辉瑞血友病药物出现患者死亡，公司回应

Core Insights - Pfizer reported a patient death during a long-term study of its hemophilia drug, Hympavzi, which led to a stock price drop of over 1% on December 23 [1] - The patient died from a stroke and intracerebral hemorrhage on December 14, as confirmed by the European Hemophilia Consortium [1] - Pfizer stated that it does not expect this incident to impact the safety of patients receiving the drug, based on current clinical data [1] Group 1 - The patient involved was part of a long-term study for Hympavzi, a long-acting clotting factor therapy approved in the U.S. for patients aged 12 and older with hemophilia A or B [1] - Hympavzi is administered weekly and aims to prevent or reduce bleeding by targeting clotting proteins [1] - Pfizer is actively gathering information in collaboration with trial researchers and an independent external data monitoring committee to understand the complexities surrounding the incident [1] Group 2 - Pfizer previously developed a one-time gene therapy, Beqvez, for treating moderate to severe hemophilia B in adults, which was approved in the U.S. [2] - However, due to high costs and weak demand, Pfizer announced the cessation of global development and commercialization of its hemophilia gene therapy earlier this year [2]